2024

article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

“There is more than one way to skin a cat” is a rather gruesome British idiom, but its sentiment surely applies to running a successful pharmaceutical portfolio. It is now more than a decade since Francesco De Rubertis, together with Kevin Johnson and Michele Olier, coined the term “asset-centric” investing to describe the approach to portfolio creation that still underpins the strategy at Medicxi.

article thumbnail

Early Impact Of The Inflation Reduction Act On Drug Discovery

Forbes: Drug Truths

There is another aspect of this provision of the IRA that is starting to be felt – "the small molecule penalty"

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Efficacy of Fluoxetine and (R,S) Ketamine in Attenuating Conditioned Fear Behaviors in Male Mice [Behavioral Pharmacology]

ASPET

Post-traumatic stress disorder (PTSD) is caused by exposure to a traumatic or stressful event. Symptoms related to this disorder include persistent re-experiencing of memories and fear generalization. Current pharmacological treatments for PTSD are insufficient, with fewer than 30% of patients reporting symptom remission. This study aims to determine the efficacy of acute ( R,S) ketamine and chronic fluoxetine (FLX) in reducing fear memory and fear generalization.

Treatment 190
article thumbnail

Nitrogen?containing heterocyclic compounds: A ray of hope in depression?

Chemical Biology and Drug Design

Role of serotonin, dopamine, and norepinephrine in neural functions and symptoms involved during their altered levels. Abstract Depression is not similar to daily mood fluctuations and temporary emotional responses to day-to-day activities. Depression is not a passing problem; it is an ongoing problem. It deals with different episodes consisting of several symptoms that last for at least 2 weeks.

Drugs 189
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

New drug triggers rapid cell death in cancer models

Broad Institute

New drug triggers rapid cell death in cancer models By Karen Zusi-Tran October 29, 2024 Breadcrumb Home New drug triggers rapid cell death in cancer models BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models. By Karen Zusi-Tran October 29, 2024 Credit: National Cancer Institute Human cells with acute myelocytic leukemia (AML) in the pericardial fluid.

Drugs 133

More Trending

article thumbnail

NASA satellites reveal abrupt drop in global freshwater levels

Science Daily: Pharmacology News

The Earth's total amount of freshwater dropped abruptly starting in May 2014 and has remained low ever since. The shift could indicate Earth's continents have entered a persistently drier phase.

145
145
article thumbnail

An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?

BioPharma Drive: Drug Pricing

An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under regulatory scrutiny.

Trials 144
article thumbnail

FDA Warns of Toxic Lead in Cinnamon Products

Drugs.com

WEDNESDAY, March 6, 2024 -- The U.S. Food and Drug Administration issued a health advisory Wednesday warning consumers that six brands of ground cinnamon are tainted with lead. The FDA urged folks to throw away and not buy the following brands of.

FDA 145
article thumbnail

AI Uses Zero-Shot Learning to Find Existing Drugs for Treating Rare Diseases

Nvidia Developer: Drug Discovery

A groundbreaking drug-repurposing AI model could bring new hope to doctors and patients trying to treat diseases with limited or no existing treatment options. A groundbreaking drug-repurposing AI model could bring new hope to doctors and patients trying to treat diseases with limited or no existing treatment options. Called TxGNN, this zero-shot tool helps doctors find new uses for existing drugs for conditions that might otherwise go untreated.

Disease 137
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Models of Life

Codon

2024 Statistical models of organisms have existed for decades. The earliest ones relied on simple linear regression and attempted to correlate genetic variations with observable traits or disease risks — such as drug metabolization rates or cancer susceptibility. As computational power increased and machine learning techniques advanced, the models’ sophistication grew.

article thumbnail

Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype

DrugBaron

This month’s announcement that Alphabet’s Isomorphic Labs, led by the talented and charismatic Deepmind co-founder Demis Hassabis, had inked discovery collaboration deals with both Lilly and Novartis was just the latest indication that AI-enabled pharma R&D was ready for the big time. Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not ju

article thumbnail

Does Federally Funded Research Justify A Piece Of Pharma’s Profits?

Forbes: Drug Truths

The thought that all drugs arise from government funded research is a fallacy.

Research 222
article thumbnail

Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder [Minireview]

ASPET

Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that develops following exposure to a traumatic event. Individuals with this condition experience numerous physiological and behavioral alterations, including intrusive memories, avoidance of trauma-related stimuli, heightened anxiety, hypervigilance, impaired cognition, elevated resting heart rate and blood pressure, and altered neuroendocrine function, to name a few.

Treatment 189
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Curcumin affects apoptosis of colorectal cancer cells through ATF6?mediated endoplasmic reticulum stress

Chemical Biology and Drug Design

Curcumin activates ATF6-regulated endoplasmic reticulum (ER) stress, promotes ATF6 nuclear translocation, activates Chop/Bax/Bcl-2/Caspase-3 apoptosis pathway, and promotes apoptosis of CRC cells. Abstract Colorectal cancer (CRC) is the main cause of cancer-associated death. Herein, we treated SW620 and HT-29 CRC cells with different curcumin concentrations, followed by treatment with the half maximal inhibitory concentration (IC50) curcumin/endoplasmic reticulum stress (ERS) inhibitor 4-phenyl

article thumbnail

Prime editing efficiently corrects cystic fibrosis mutation in human lung cells

Broad Institute

Prime editing efficiently corrects cystic fibrosis mutation in human lung cells By Allessandra DiCorato July 10, 2024 Breadcrumb Home Prime editing efficiently corrects cystic fibrosis mutation in human lung cells The approach targets the most common genetic cause of the disease and could enable a one-time treatment as effective as existing daily therapies.

article thumbnail

The science of ageing and restoring healthspan

Drug Target Review

What is “healthspan” and how does it relate to Life Bioscience’s mission? It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. If we take into consideration the timeframe of our lives, our “healthspan” is defined as the number of healthy years we live, which is different than our lifespan, the number of years of life.

Science 145
article thumbnail

Moderate coffee and caffeine consumption is associated with lower risk of developing multiple cardiometabolic diseases, new study finds

Science Daily: Pharmacology News

Consuming moderate amounts of coffee and caffeine regularly may offer a protective effect against developing multiple cardiometabolic diseases, including type 2 diabetes, coronary heart disease and stroke, according to new research.

Disease 144
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Wave sees RNA editing validation in early trial results

BioPharma Drive: Drug Pricing

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

RNA 143
article thumbnail

Silly Things Large Language Models Do With Molecules

Practical Cheminformatics

“Pay no attention to the man behind the curtain” - The Wizard of Oz Introduction Recently, a few groups have proposed general-purpose large language models (LLMs) like ChatGPT , Claude , and Gemini as tools for generating molecules. This idea is appealing because it doesn't require specialized software or domain-specific model training. One can provide the LLM with a relatively simple prompt like the one below, and it will respond with a list of SMILES strings.

article thumbnail

COVID Can Threaten Sickle Cell Patients, But Too Few Are Vaccinated

Drugs.com

FRIDAY, Jan. 12, 2024 -- Sickle cell disease is one of many chronic health conditions that dramatically increases the risk of hospitalization and death in people infected by COVID-19.Unfortunately, folks with sickle cell disease are much less.

Vaccine 141
article thumbnail

Where's the Synthetic Blood?

Codon

Dr. Keith Neeves gives a history of blood transfusions and explains why it will be difficult to scale up the creation of synthetic blood for Issue 03 of Asimov Press. We are mostly blood. Of the 36 trillion cells in the human body, 32 trillion are blood cells. These blood cells synchronize the delivery of oxygen to every tissue in your body, fight pathogens, and heal wounds.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Just in time for new years’ reflections and resolutions, this year’s JPM felt like a refreshing burst of enthusiasm for a sector that has seen its challenges in 2022 and 2023 but also some green shoots. 2023 was a stellar year for M&A, comeback stories, burgeoning “hot” spaces, and for re-learning the basics of belt-tightening and careful capital allocation.

article thumbnail

Will Biopharma Companies Shun Vaccine R&D In A New Pandemic?

Forbes: Drug Truths

Only biopharma could have combated Covid-19; no other industry has the capacity to do so. When the world was in crisis, this industry responded. If need be, it will again, despite the financial consequences.

Vaccine 214
article thumbnail

Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities [Commentary]

ASPET

Cannabis and its products have been used for centuries for both medicinal and recreational purposes. The recent widespread legalization of cannabis has vastly expanded its use in the United States across all demographics except for adolescents. Meanwhile decades of research have advanced our knowledge of cannabis pharmacology and particularly of the endocannabinoid system with which the components of cannabis interact.

Research 189
article thumbnail

High cannabigerol hemp extract moderates colitis and modulates the microbiome in an inflammatory bowel disease model [Gastrointestinal, Hepatic, Pulmonary, and Renal]

ASPET

Cannabis sativa L. has a long history of medicinal use, particularly for gastrointestinal diseases. Patients with inflammatory bowel disease (IBD) report using cannabis to manage their symptoms, despite little data to support the use of cannabis or cannabis products to treat the disease. In this study, we utilize the well-described dextran sodium sulfate (DSS) model of colitis in mice to assess the impact of commercially available, non-euphorigenic, high cannabigerol (CBG) hemp extract (20 mg/mL

Disease 189
article thumbnail

KVX-053, a Protein Tyrosine Phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1 - induced acute lung injury in mice [Gastrointestinal, Hepatic, Pulmonary, and Renal]

ASPET

The Acute Respiratory Distress Syndrome (ARDS), often preceded by acute lung injury (ALI), is characterized by the accumulation of inflammatory fluid in the lung alveoli, leaky alveolar epithelium and endothelium, and overexpression of pro-inflammatory cytokines. This progression from ALI to ARDS is a major contributor to the high mortality observed in COVID-19 patients.

186
186
article thumbnail

Suppression of mast cell activation by GPR35: GPR35 is a primary target of disodium cromoglycate [Inflammation, Immunopharmacology, and Asthma]

ASPET

Mast cell stabilizers including disodium cromoglycate (DSCG) were found to have potential as the agonists of an orphan G protein-coupled receptor, GPR35, although it remains to be determined whether GPR35 is expressed in mast cells and involved in suppression of mast cell degranulation. Our purpose in this study is to verify the expression of GPR35 in mast cells, and to clarify how GPR35 modulates the degranulation.

189
189
article thumbnail

The minor phytocannabinoid delta-8-tetrahydrocannabinol attenuates collagen-induced arthritic inflammation and pain-depressed behaviors [Behavioral Pharmacology]

ASPET

Patients with arthritis report using cannabis for pain management, and the major cannabinoid 9 -THC has anti-inflammatory properties, yet the effects of minor cannabinoids on arthritis are largely unknown. The goal of the present study was to determine the antiarthritic potential of the minor cannabinoid 8 -THC using the collagen-induced arthritis (CIA) mouse model.

Treatment 186
article thumbnail

The Potential of Cannabichromene (CBC) as a Therapeutic Agent [Minireview]

ASPET

There is a growing interest in the use of medicinal plants to treat a variety of diseases, and one of the most commonly used medicinal plants globally is Cannabis sativa. The two most abundant cannabinoids ( 9 -tetrahydrocannabinol and cannabidiol) have been governmentally approved to treat selected medical conditions; however, the plant produces over 100 cannabinoids, including cannabichromene (CBC).

article thumbnail

Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine [Behavioral Pharmacology]

ASPET

3,4-Methylenedioxymethamphetamine (MDMA) has shown efficacy as a medication adjunct for treating post-traumatic stress disorder (PTSD). However, MDMA is also used in non-medical contexts that pose risk for cardiovascular and neurological complications. It is well established that MDMA exerts its effects by stimulating transporter-mediated release of the monoamines, 5-hydroxytryptamine (5-HT), norepinephrine, and dopamine.

Drugs 184